Bluebird bio appoints new CFO to oversee financial restatements
Adds background throughout
May 29 (Reuters) -Gene therapy maker bluebird bio BLUE.O on Wednesday named former Renalytix RENX.L finance chief James Sterling as its CFO to oversee the revision of the company's financial statements.
Sterling will take over on June 10 from incumbent Chris Krawtschuk, who was in the role from November 2022.
The company announced its plans to revise its financial statements in March, citing "material weakness in its internal control over financial reporting".
It planned to restate its financials for 2022 and the first three quarters of last year due to accounting errors related to some contract manufacturing agreements.
The company has contract manufacturing agreements with Thermo Fisher Scientific TMO.N and Lonza, among others, according to its annual report released last year.
Bluebird makes three gene therapies, including sickle cell disease treatment Lyfgenia. The therapy was approved last year and is expected to generate revenue from the third quarter.
The company posted total revenues of $29.5 million for 2023, a jump from $3.6 million a year earlier, but much lower than analysts' average estimate of $40.6 million, according to LSEG estimates.
The company had flagged 'going concern' doubts last year due to insufficient cash reserves to run operations.
As of March 31, bluebird had cash, cash equivalents and restricted cash balance of about $264 million.
Shares of Massachusetts-based bluebird fell 1% to 93 cents in premarket trading.
Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli and Shailesh Kuber
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
